Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2020

View Archived Issues

Enrollment ongoing in phase I/II study of oral BDTX-189 in advanced solid tumors

Sanofi initiates phase III study of SAR-408701 in CEACAM5-positive metastatic nonsquamous NSCLC

Novel muraminomicin derivatives with potent activity in MRSA infection models

OXi-4503 in combination with ARA-C shows safety and early clinical efficacy in AML

ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy

Suzhou Mednes Pharma Tech patents hedgehog signaling inhibitors

Roche discloses new EGFR mutant inhibitors

B cells help T cells succeed during checkpoint blockade

Single transcription factor enables chronic toxoplasma infection

AlzeCure Pharma presents Trk-A and/or Trk-B and/or Trk-C modulators

Meiji Seika Pharma describes new PDE4 inhibitors

New compounds for Huntington's disease presented by PTC Therapeutics

Pfizer begins phase III study of PF-06801591 in high-risk nonmuscle invasive bladder cancer

Xalud starts phase II study of XT-150 for pain due to knee osteoarthritis

SUMOylation inhibition enhances targeting of farnesoid X receptor for liver fibrosis

Kadmon discloses new SLC2A3 inhibitors

Oncogene Ras affects memory consolidation

Phase III study of surufatinib in pancreatic neuroendocrine tumors stopped early for efficacy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...